Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Claire (Xiaoyu) Zhang

Goodwin Procter

main

Zhang Claire Xiaoyu

Zhang Claire

Goodwin Associate Claire Zhang, from New York, practices in Business Law.

Claire (Xiaoyu) Zhang

Experience

Areas of Practice

Credentials

Education

JD2022

LLB2019

Admissions

Bars

Related Content

Goodwin Advises Biotheus in Agreement to be Acquired by BioNTech for $800 Million Upfront and $150 Million in Milestones

Goodwin Advises Curon Biopharmaceutical in Acquisition of CN201 by Merck for $700 Million Upfront Plus up to $600 Million Milestones

Human Immunology Biosciences to be Acquired by Biogen For $1.15 Billion Upfront and up to $650 Million in Potential Milestone Payments

Proteologix to be Acquired by Johnson & Johnson For $850 Million

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

EQRx’s Acquisition by Revolution Medicines is Complete

EQRx To Be Acquired By Revolution Medicines In All-Stock Transaction

Technology

Life Sciences

Venture Capital

New Company Formation

Technology M&A

Mergers & Acquisitions